REDWOOD CITY, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will participate in the following investor conferences:
A live audio webcast and an archive of the presentations from UBS Biopharma and Evercore ISI HealthCONx conferences will be available on the investors’ page of the Coherus website at http://investors.coherus.com.
Coherus Contact Information:
Jami Taylor
VP, Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.19 |
| Daily Change: | 0.03 2.59 |
| Daily Volume: | 953,423 |
| Market Cap: | US$138.310M |
August 07, 2025 May 12, 2025 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
